MENU
+Compare
STRO
Stock ticker: NASDAQ
AS OF
Apr 2 closing price
Price
$0.63
Change
+$0.03 (+5.00%)
Capitalization
52.81M

STRO Sutro Biopharma Forecast, Technical & Fundamental Analysis

Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company... Show more

STRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for STRO with price predictions
Apr 02, 2025

STRO's RSI Indicator stays in oversold zone for 13 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where STRO advanced for three days, in of 265 cases, the price rose further within the following month. The odds of a continued upward trend are .

STRO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where STRO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for STRO entered a downward trend on April 02, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.184) is normal, around the industry mean (13.260). P/E Ratio (0.000) is within average values for comparable stocks, (64.931). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.878). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (0.781) is also within normal values, averaging (252.036).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. STRO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STRO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
STRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

STRO is expected to report earnings to rise 2.81% to -85 cents per share on May 19

Sutro Biopharma STRO Stock Earnings Reports
Q1'25
Est.
$-0.85
Q4'24
Est.
$-0.83
Q3'24
Beat
by $0.14
Q2'24
Beat
by $0.20
Q1'24
Missed
by $0.03
The last earnings report on March 13 showed earnings per share of -82 cents, meeting the estimate of -82 cents. With 1.11M shares outstanding, the current market capitalization sits at 52.81M.
A.I. Advisor
published General Information

General Information

a developer of new products in protein vaccines and therapeutics

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
111 Oyster Point Boulevard
Phone
+1 650 881-6500
Employees
324
Web
https://www.sutrobio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
UBS30.450.10
+0.33%
UBS Group AG
WHR90.78-0.38
-0.42%
Whirlpool Corp
PRT4.10-0.17
-3.91%
PermRock Royalty Trust Trust
NVTS1.91-0.09
-4.50%
Navitas Semiconductor Corp
BB3.39-0.34
-9.12%
BlackBerry Limited

STRO and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, STRO has been loosely correlated with ATXS. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if STRO jumps, then ATXS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STRO
1D Price
Change %
STRO100%
+5.90%
ATXS - STRO
44%
Loosely correlated
+2.22%
ALGS - STRO
44%
Loosely correlated
+6.16%
TRDA - STRO
42%
Loosely correlated
+0.46%
GBIO - STRO
40%
Loosely correlated
+0.57%
CRNX - STRO
40%
Loosely correlated
+2.51%
More